Vimarsana
Biggest News Aggregation in the World

Page 2 - Danielj Oconnor News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Danielj Oconnor. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Danielj Oconnor Today - Breaking & Trending Today

Ambrx Biopharma Inc. (NYSE:AMAM) Receives $21.88 Average Price Target from Brokerages - Vimarsana News

Ambrx Biopharma Inc. (NYSE:AMAM) Receives $21.88 Average Price Target from Brokerages

Shares of Ambrx Biopharma Inc. (NYSE:AMAM – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eight brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price […]

Source: wkrb13.com
Baystreet.ca - Ambrix to Join NASDAQ Biotech Index - Vimarsana News

Baystreet.ca - Ambrix to Join NASDAQ Biotech Index

Ambrx Biopharma, Inc. (NASDAQ: AMAM) opened trading Thursday down, on the announcement of its addition to the NASDAQ Biotechnology Index effective prior to the market open on Monday, December 18. “2023 has been a transformational year for Ambrx, ...

Ambrx Biopharma Inc. (NYSE:AMAM) Receives Average Rating of "Moderate Buy" from Analysts - Vimarsana News

Ambrx Biopharma Inc. (NYSE:AMAM) Receives Average Rating of "Moderate Buy" from Analysts

Ambrx Biopharma Inc. (NYSE:AMAM – Get Free Report) has received a consensus rating of “Moderate Buy” from the eight research firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year target […]

Source: wkrb13.com
Insider Selling: Ambrx Biopharma Inc. (NYSE:AMAM) CEO Sells 50,012 Shares of Stock - Vimarsana News

Insider Selling: Ambrx Biopharma Inc. (NYSE:AMAM) CEO Sells 50,012 Shares of Stock

Ambrx Biopharma Inc. (NYSE:AMAM – Get Free Report) CEO Daniel J. O’connor sold 50,012 shares of the company’s stock in a transaction dated Friday, October 27th. The stock was sold at an average price of $9.82, for a total value of $491,117.84. Following the completion of the sale, the chief executive officer now directly owns […]

Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress - Vimarsana News

Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress

Newly published abstract regarding dose escalation patients provides key updates including: ≥50% PSA reduction observed across putative therapeutic dose levels ≥2.0 mg/kg – 3 of 3 in Cohort 6...